Pre-meeting Session:
PW8. TB Workshop $
Wednesday, October 2, 2013: 8:00 AM-12:00 PM
Room: The Moscone Center: 270-276
Co-organized with the Center for Global Health Policy

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • review the pipeline of new drugs and recent or ongoing studies of new strategies for treating active tuberculosis (TB)
  • outline recommendations for preventing, diagnosing, and treating mycobacterial infections in the setting of TNF-inhibitors or other immuno-modulating agents
  • review the latest data about what programmatic interventions are effective in high burden settings
  • discuss alternative viewpoints for whether targeted versus generalized adoption of interferon-gamma release assay (IGRA) for diagnosis of TB infection is most cost effective
  • review successful strategies for treating multidrug-resistant (MDR) TB in the United States

Target Audience: scientists, researchers, public health practitioners, pharmacists, nurses, microbiologists, members-in-training, investigators, infectious diseases physicians, infectious diseases pediatricians, infection preventionists, hospital epidemiologists, HIV specialists, HIV clinicians, health care workers, fellows, epidemiologists, clinicians, academicians

Tracks: Pediatric ID, Global ID, Adult ID

Pre-Meeting Workshop Moderator:  Carol Dukes Hamilton, MD, MHS, FHI 360

CME Credits: Maximum of 4.0 hours of AMA PRA Category 1 CreditTM

ACPE Credits: ACPE 4.0 knowledge-based contact hours (0.4 CEU) of pharmacy CE

ACPE Number: 0221-9999-13-113-L01-P


C. Dukes Hamilton, None

R. Reves, None

J. Stout, None

D. Havlir, Gilead: Gilead donates drugs to an NIH study I lead. I receive NO direct funding from Gilead., Only drugs donated for an NIH study I lead. NO OTHER financial benefit

C. Dukes Hamilton, None

See more of: Pre-meeting Session

Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.